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PURPOSE. Research over the past 25 years at the University of Cape Town has led to the
identification of causative mutations in 17% of the 1416 families in the Retinal Degenerative
Diseases (RDD) biorepository in South Africa. A low rate of mutation detection has been
observed in patients of indigenous African origin, hinting at novel genes and mutations in this
population. Recently, however, data from our translational research program showed two
unrelated indigenous African families with Usher syndrome (USH), with the same
homozygous MYO7A mutation. Therefore, the extent to which this mutation contributes
toward the disease burden in South Africa was investigated.
METHODS. Cohorts of unrelated indigenous South African probands with different RDD
diagnoses were tested for the MYO7A c.6377delC mutation. Familial cosegregation analysis
was performed for homozygous probands, clinical data were evaluated, and SNP haplotypes
were analyzed.
RESULTS. This homozygous MYO7A mutation underlies a remarkable 43% of indigenous African
USH cases investigated in this study, the majority of which (60%) were diagnosed clinically
with Type 2 USH. All homozygotes shared a common haplotype. This mutation does not
appear to cause nonsyndromic vision loss.
CONCLUSIONS. Of interest is the origin of this common mutation relevant to the Bantu
population migration into southern Africa. Further investigation of the phenotype may
elucidate the disease biology, and perhaps reveal a larger cohort with the same mutation, with
which to assess the impact of environmental and genetic modifiers and evaluate therapeutic
trials.
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Usher syndrome (USH) is characterized by vision andhearing loss, and is the most common cause of deaf-
blindness.1,2 It is an autosomal recessively inherited group of
disorders, divided into three major clinical subtypes that are
differentiated by the severity of hearing loss and the presence
of vestibular dysfunction. Vision loss due to retinitis pigmentosa
(RP) is a hallmark of all three USH subtypes. In addition to
clinical heterogeneity, Usher syndrome displays genetic hetero-
geneity, with 12 causative genes identified to date.3
Usher syndrome type 1 is the most severe form, exhibiting
profound congenital hearing loss and vestibular dysfunction,
and prepubertal onset of progressive RP. To date, six genes have
been associated with USH type 1, namely CDH23, CIB2,
MYO7A, PCDH15, USH1C, and USH1G.4 Usher syndrome type
2 is less severe, characterized by congenital hearing loss that is
moderate to severe, with normal vestibular functioning and a
later RP onset. Mutations in three genes, namely DFNB31,
GRP98, and USH2A, cause type 2 USH.1,2 Type 3 USH is
characterized by variable onset of RP and hearing loss, as well
as varying degree of vestibular dysfunction. Two genes are
associated with USH type 3, namely CLRN12 and HARS,5 with a
third gene (ABHD12) being associated with a variant of this
subtype.6
A number of USH protein interactions (or interactomes)
have been reported,4,7 which function in the development and
maintenance of stereocilia hair bundles of the inner ear and
which also colocalize in the synaptic layer, connecting cilium
and the calyceal processes of the photoreceptors of the retina.
The exact function of these protein interactomes is not known,
as mouse models (of mutated USH genes) have little or no
retinal phenotype, but they may have a role in protein
trafficking between the inner and outer segments of the
photoreceptors, as well as synaptic function of these sensory
neurons.4
Due to the genetic and clinical heterogeneity, the large size
of the genes, and multiple isoforms underlying the syndrome,
identifying the molecular basis of USH in affected South African
families using traditional candidate gene screening methods has
been challenging. Technologic advances, such as the develop-
ment of microarrays and next generation sequencing, have
significantly improved the turnaround time and success rates of
genetic mutation screening for inherited retinal degenerative
diseases. As part of our translational research program in South
Africa.8,9 families can opt for genetic screening using micro-
arrays (Asper Biotech Ltd., Tartu, Estonia)10 or for whole exome
sequencing of 105 retinal candidate genes (through the
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Manchester Centre for Genomic Medicine, Central Manchester
University Hospitals NHS Foundation Trust, Manchester, UK).11
A review of data obtained from the Asper USH array and whole
exome analyses revealed two unrelated indigenous (Black)
South African USH probands with a homozygous c.6377delC
(p.Pro2126Leufs*5) mutation in MYO7A, which subsequently
was confirmed by cycle sequencing. This mutation has been
reported previously only recently (to the best of our
knowledge) in the compound heterozygous state, together
with p.Arg1240Trp, in a single Caucasian individual from the
United Kingdom with USH type 1.12 The mutation subsequent-
ly was added to the panel of mutations on the Asper Usher
Microarray; however, many South African samples had been
tested by that time and, therefore, it was deemed necessary to
rescreen appropriate samples for this mutation. The
p.Pro2126Leufs*5 mutation is predicted to truncate the 2215
amino acid MYO7A protein by 86 amino acids (3.88%).
The gene MYO7A was the first USH gene identified13 and
has since been recognized as the most frequent cause of USH
type 1, which is the most severe form of USH.14,15 The protein
MYO7A is an unconventional myosin expressed in multiple
epithelial cell types,16 including the RPE, where it functions in
the light-dependent localization of the visual cycle enzyme,
RPE65.17 It is also expressed in the photoreceptor calyceal
processes and cilia, and the stereocilia, together with other
USH proteins.
The identification of two unrelated indigenous South
African patients (and their respective families) with the same
homozygous MYO7A mutation warranted further investigation
in this population, particularly with respect to a potential
founder effect and the clinical manifestation of c.6377delC.
Phenotypic variation has been reported previously in USH,
with mutations in USH2A causing nonsyndromic RP18,19 and
MYO7A mutations causing nonsyndromic20 deafness. Founder
mutations have been reported previously in indigenous South
Africans,21,22 and determining whether this USH mutation
occurs on the same haplotype in all affected individuals would




Affected individuals and their family members were recruited
from throughout South Africa as part of a Retinal Degenerative
Disorders (RDD) research project, established in the Division
of Human Genetics at the University of Cape Town in 1990.
Biological material (genomic DNA extracted from venous
blood) is archived in the RDD registry, together with
demographic and clinical information. Informed consent is
obtained from all RDD research participants according to the
tenets of the Declaration of Helsinki (2013), and ethics
approval for this specific study was obtained from the
institutional Human Research Ethics committee (HREC/REF:
312/2014).
A cohort of 12 unrelated indigenous South African probands
with confirmed clinical diagnoses of USH (regardless of the
clinical subtype), but no genetic diagnoses, were tested for the
c.6377delC mutation. A further six indigenous South African
probands with RDD and some hearing loss, but no clinical
confirmation of USH, also were tested and considered to be a
‘‘query USH cohort.’’ Testing also was performed on samples
from three probands of Mixed Ancestry with confirmed clinical
diagnoses of USH (who likely share similar ancestry with the
indigenous South African individuals, as Bantu-speaking
Africans are a major ancestral contributor to this admixed
population23).
Familial cosegregation analysis was performed where
possible for probands carrying the homozygous c.6377delC
mutation, to ensure that the mutation cosegregated with
disease within the families. A total of 51 indigenous South
African population controls, who had not specifically been
assessed for the absence of RDD, also was screened for the
mutation. No detailed population data were available for these
controls, other than that they are of indigenous South African
origin. To investigate possible phenotypic variation, a cohort of
10 indigenous South African probands with nonsyndromic
autosomal recessive RP (arRP) and 107 indigenous South
African simplex RP cases also were tested.
c.6377del C Assay Design
The MYO7A Transcript variant 1 NCBI (NM_000260, accessed
November 2013) and Ensembl (ENSG00000137474,
ENST00000409709, accessed November 2013) sequences
were used to compare the region containing exon 47 and to
ensure that the entire exon was included in the assay.
Transcript variant 1 was selected as it encodes the longest
isoform. Primers were designed to span exon 47 and at least 50
bp of intronic sequence flanking the exon. The primers used
were Forward 50 GCAACAGGAGAGGCTGACTTTATC 30, Re-
verse 50 GTGGCTAGGAGGGCTTGTG 30.
The primers were used to amplify a 287 bp fragment under
standard 25-lL PCR conditions: 100 ng genomic DNA, 0.4 lM
forward and reverse primer, 200 lM dNTPS, 1X Colourless
GoTaq Reaction Buffer, and 0.5U GoTaq DNA Polymerase
(Promega, Madison, WI, USA). Cycling conditions were as
follows: 958C – 5 minutes, 30 cycles of (948C – 30 seconds,
618C – 30 seconds, 728C – 40 seconds), 728C – 7 minutes.
The c.6377delC mutation creates an Hpy188III restriction
enzyme recognition site 131 bp into the amplicon, resulting in
156 bp and 131 bp fragments in samples with the homozygous
mutation, and 287, 156, and 131 bp fragments in samples with
the heterozygous mutation. Restriction digests with Hpy188III
were performed as follows: a standard 20-lL reaction
containing 10 lL PCR product, 1X NEB CutSmart Buffer, and
5U NEB Hpy188III enzyme (New England Biolabs, Ipswich,
MA, USA) was incubated at 378C for 3 hours. The digest
products were subjected to electrophoresis on a 3% agarose gel
containing SYBR Safe DNA Gel Stain (Applied Biosystems by
Life Technologies, Woolston, Warrington, UK) and visualized
under UV light using a UVIpro Gold transilluminator (UVItec,
Cambridge, UK). A heterozygous and homozygous sample
(confirmed by cycle sequencing) were included as controls.
Haplotype Analysis
To examine the possibility of a founder effect in the indigenous
South African population (which would have diagnostic
implications), it was necessary to determine whether the
mutation exists on a common haplotype in the cases.
Additionally, haplotyping of African controls could determine
the origin of the mutation in South Africa, and the potential
contribution to USH disease burden in other African countries.
The mutation of interest is located at position 76924019 on
chromosome 11 (human genome build GRCh37.p13/hg19).
More than 1 Mb of the sequence flanking the mutation (584
709bp 50 and 502 265bp 30) was interrogated for informative
SNPs with minor allele frequencies > 20% in the Luhya and
Yoruba 1000 Genomes dataset.24 Three single nucleotide
polymorphisms (SNPs) were selected for haplotyping analysis
in mutation-positive families: rs6592706, rs948972, and
Usher Syndrome in Indigenous South Africans IOVS j October 2015 j Vol. 56 j No. 11 j 6672
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/934564/ on 10/19/2015
rs11237122. All selected SNPS are 50 of the mutation; no
suitable SNPs were identified 30 of the mutation (Fig. 1).
Primers were designed to amplify a 250, 210, and 247 bp
fragment spanning rs6592706, rs948972, and rs11237122,
respectively. Polymerase chain reactions (PCR) were per-
formed in a 25-lL volume under standard PCR conditions:
100 ng genomic DNA, 0.4 lM forward and reverse primer, 200
lM dNTPS, 1X Colourless GoTaq Reaction Buffer and 0.5U
GoTaq DNA Polymerase (Promega). Cycling conditions were as
follows: 958C – 5 minutes, 30 cycles of (948C – 30 seconds,
annealing temperatures (Ta) – 30 seconds, 728C – 40 seconds),
728C – 7 minutes. Primer sequences, annealing temperatures,
and assay information are listed in Table 1.
The G allele of rs6592706 creates a BsrBI restriction
enzyme recognition site, generating fragments of the following
sizes for the various genotypes: A/A, 250 bp; A/G, 250, 159,
and 91 bp; G/G, 159 and 91 bp. Restriction digests were
performed as follows: a standard 20 lL reaction containing 10
lL PCR product, 1X Tango Buffer, and 2U BsrBI enzyme
(ThermoScientific, Waltham, MA, USA) was incubated at 378C
for 3 hours. The digest products were subjected to electro-
phoresis on a 3% agarose gel containing SYBR Safe DNA Gel
Stain (Applied Biosystems by Life Technologies) and visualized
under UV light.
The C and G alleles of rs948972 were distinguished by cycle
sequencing following purification of PCR products; 8.9 lL PCR
products were purified by 1U FastAP Shrimp Alkaline
Phosphatase (ThermoScientific) and 2U Exonuclease I (Ther-
moScientific) in a 10-lL reaction that was incubated as follows:
378C – 60 minutes, 758C – 15 minutes, 958C – 5 minutes. Cycle
sequencing was performed in a 20-lL reaction containing the
10 lL purified PCR products, 1 lM reverse primer, 1X
Sequencing Buffer, and 1X BigDye Terminator v3.1 Reaction
Mix (Applied Biosystems by Life Technologies). Cycling
conditions were: 968C – 5 minutes, 30 cycles of (968C – 30
seconds, 508C – 15 seconds, 608C – 4 minutes). Sequencing
products were purified by ethanol precipitation and resus-
pended in 10 lL Sabax water (Adcock Ingram, Johannesburg,
South Africa), after which 5 lL sequencing reaction was
loaded, together with 8 lL Hi-Di Formamide (Applied
Biosystems by Life Technologies), onto a 3130xl Genetic
Analyser (Applied Biosystems by Life Technologies).
The T allele of rs11237122 creates a PflMI restriction
enzyme recognition site, generating fragments of the following
sizes for the various genotypes: C/C, 247 bp; C/T, 247, 138, and
109 bp; T/T, 138 and 109 bp. Restriction digest were performed
as follows: a standard 20-lL reaction containing 10 lL PCR
product, 1X Buffer R and 2U PflMI enzyme (ThermoScientific)
was incubated at 378C for 3 hours. The digest products were
subjected to electrophoresis on a 3% agarose gel containing
SYBR Safe DNA Gel Stain (Applied Biosystems by Life
Technologies) and visualized under UV light.
Haplotypes of affected individuals with the homozygous
c.6377delC mutation were constructed manually based on
segregation within the families, and then compared between
families, and compared to control data; individual genotypes
for the 3 SNPs were obtained from 97 Luhya and 88 Yoruba
individuals in the 1000 Genomes dataset.24 Linkage disequilib-
rium testing and haplotype analysis was performed subse-
quently, and v2 and Pearson’s P values were calculated, using
the SHEsis online program (available in the public domain at
http://analysis.bio-x.cn/myAnalysis.php).25,26
RESULTS
Frequency of c.6377del C
After the initial identification of two unrelated indigenous USH
probands homozygous for c.6377delC, another four unrelated
homozygotes were identified by screening 12 additional
probands. Thus, a total of six homozygotes was identified in
the total cohort of 14 confirmed indigenous South African USH
cases (42.86%).
No mutation-positive individuals were identified in the
additional cohorts screened (Table 2). Furthermore, the
mutation was not present in the Luhya or Yoruba individuals
in the 1000 Genomes dataset,24 nor was it present in 200
chromosomes from Zulu individuals sequenced as part of the
African Genome Variation Project (AGVP).27
USH Mutation-Positive Families: Cosegregation and
Haplotyping Analysis
The six identified families came from the following ethno-
linguistic groups: one Sotho, two Zulu, two Xhosa, and one
unknown indigenous South Africans. The families live in two
large, geographically distinct provinces in South Africa, and
each family lives in a different town, indicating that consan-
guinity was unlikely. Familial DNA was available for three of the
six probands, and familial cosegregation analysis confirmed
that the mutation cosegregated with disease within these
families (Fig. 2). Genotyping of 3 SNPs (>83kB from
c.6377delC) in all available familial DNA samples also showed
the total of 10 homozygotes all shared a common haplotype
(Fig. 2). The clinical and demographic information pertaining
to the affected individuals is presented in Table 3.
FIGURE 1. Diagrammatic representation of the >1 Mb region of
chromosome 11 (between [A] and [B]) interrogated for informative
SNPS, and the three SNPs selected for genotyping (SNP1¼ rs6592706,
SNP2 ¼ rs948972, and SNP3 ¼ rs11237122). The mutation location is
shown as a bold vertical arrow. The numbers below the horizontal
solid line indicate the position (bp) on the chromosome, the numbers
above the horizontal arrows show the distance between adjacent
SNPS, and numbers above the dashed line show the distance between
each SNP and c.6377delC. The MYO7A gene is represented as a gray
box (located from 76839310–76926284 bp).
TABLE 1. Primer Sequences, PCR Annealing Temperatures (Ta), and Assay Information for the Genotyping of Three SNPs in Families Carrying the
c.6377delC Mutation
SNP Fwd Primer, 5030 Rev Primer, 5030 Ta, 8C Assay
rs6592706 cttgaaggtggtctagttctca atgtggattcaacagggcca 60 þ BsrBI
rs948972 agtccaagctcacagaggag acactcctgtctgcctgatc 60 Cycle sequencing
rs11237122 tgctgtactttggccctgaa gcagaatctcgaagtcagagg 58 þ PflMI
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The SHEsis Linkage Disequilibrium test was used to
calculate Lewontin’s D’ and r2 between each pair of the 3
SNPs in the 1000 Genomes control data from 97 Luhya and 88
Yoruba individuals. The results indicated that there is no
linkage disequilibrium among the three SNPs in the separate
control populations or when they are combined, and,
therefore, this is not a block of low haplotype diversity in
these African population groups.
We performed v2 calculations for genotype frequencies
(Table 4) of the 3 SNPs in the 185 African controls and 6
unrelated, c.6377delC homozygous probands affected with
USH. These statistical tests showed that the cases, separate
control groups, and combined controls showed no deviation
from Hardy Weinberg Equilibrium. The v2 analysis showed a
significant difference between the Luyha and Yoruba controls
in the frequency of rs6592706 (Pearson’s P ¼ 0.017293);
however, this was no longer significant when the critical value
was set to P < 0.01666 (Bonferroni correction for testing of 3
SNPs). There was no significant difference in the frequencies of
rs948972 and rs11237122 between the Luhya and Yoruba
controls (Pearson’s P ¼ 0.122203 and 0.527811, respectively)
and, therefore, these control groups were combined for
subsequent comparison with the cases. The results showed
that for rs6592706 and rs11237122 there are significant
differences in the genotype frequencies between the cases
and controls, which remained significant after Bonferonni
correction (P < 0.01666).
Subsequently, haplotypes were reconstructed and haplo-
type frequencies compared between the 6 unrelated cases and
185 controls (Table 5). The SHEsis analysis of 370 control and
12 case haplotypes gave a Global v2 of 77.993309, while df¼6,
and a Pearson’s P value was 9.27e-015. Haplotypes occurring
with a frequency less than 0.05 were excluded. The results
indicated a significant difference in the frequency of the ACT
haplotype in the African controls compared to the six
probands with Usher syndrome.
DISCUSSION
Our experience has shown that testing for known candidate
genes and mutations for RDDs (as configured through the
Asper Biotech Ltd. Arrays28) has a good yield with our
subcohort of Caucasian subjects, with 115 of 280 patients
(41.1%) having their mutation(s) identified through the use of
various Asper arrays, but a rather low return in our indigenous
African patients, in whom only 14 of 109 patients (i.e., 12.8%)
have a genetic diagnosis after microarray screening (results not
shown). This is understandable, since most of the testing arrays
are based on mutations generally identified in cohorts of
patients of European/Caucasian origin. Our identification of a
homozygous MYO7A mutation in two USH patients of
indigenous African origin was initially surprising, but its
emergence as the cause of a large proportion (42.86%) of
TABLE 2. Results of Mutation Screening in South African Case and Control Cohorts
Cohort Screened No. Individuals No. Chromosomes
No. Chromosomes
With c.6377delC
Indigenous South African USH 14 28 12
Indigenous South African query USH 6 12 0
Mixed Ancestry USH 3 6 0
Indigenous South African arRP 10 20 0
Indigenous South African simplex RP 107 214 0
Indigenous South African controls 51 102 0
South African Zulu control AGVP data* 100 200 0
Luhya control 1000 Genomes data* 97 194 0
Yoruba control 1000 Genomes data* 88 176 0
* Control data from publically available datasets.
TABLE 3. Clinical and Demographic Data From 10 Affected c.6377delC Homozygous Individuals in 6 Families
DNA Code Ethnic Group Age of Onset, y Clinical Diagnosis and Information
RPU 318.1UNA Unknown 1 USH Type 2
RPU 340.3JEA* Xhosa Congenital USH Type 2; VA: L ¼ 6/60; R ¼ 6/12 at age 43. Congenital hearing
loss.
RPU 340.4PAT* Xhosa Congenital USH Type 2; VA: L ¼ 6/48; R ¼ 6/48 at age 40. Congenital hearing
loss.
RPU 340.5PET* Xhosa Congenital USH Type 2; VA: L ¼ 6/24; R ¼ 6/60 at age 37. Congenital hearing
loss.
RPU 340.8SIG* Xhosa Congenital Congenital hearing loss, developed RP.
RPU 564.1FRA Zulu 11 USH Type 2
RPU 954.1ELI Xhosa 6/7 USH Type 2
RPU 1136.1MAN* Zulu Congenital USH Type 1. Congenital hearing loss, RP developed at 6–8 y,
progressive loss of day and night vision.
RPU 1136.2LIN* Zulu Congenital USH Type 1. Congenital hearing loss, RP developed at 6–8 y,
progressive loss of particularly night vision.
RPU 1338.1ISI Sotho Congenital USH Type 1. VA: L ¼ 6/18; R ¼ 6/12 at age 30. Night blindness
onset at 21 y. Slow disease progression, pigment, attenuation, pale
discs.
VA, visual acuity; L, left eye; R, right eye.
* Multiple members of Family RPU 340 and Family RPU 1136.
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FIGURE 2. (A–F) Pedigrees of six c.6377delC mutation–positive individuals and their family members. Squares represent males and circles
represent females, with shaded symbols indicating individuals affected by USH. All individuals from whom DNA was available are indicated by a
DNA code. Key: The 3 SNPs and c.6377delC mutation are indicated in the order shown, with the founder haplotype shaded.
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unselected USH cases from this population group was
remarkable. Several possibilities could explain the existence
of this relatively frequent mutation underlying USH in this part
of Africa, including a mutational hotspot at this nucleotide
position of the MYO7A gene, evolutionary advantage con-
ferred, or genetic drift. The c.6377delC mutation has been
reported only once previously (in the compound heterozygous
state, in a Caucasian individual from the United Kingdom with
type I USH),12 and the mutation has not been detected in the
1000 Genomes dataset, indicating that this codon is not
particularly susceptible to mutagenesis. It is unlikely that the
mutation confers an advantage to carriers, as heterozygous
mutations in MYO7A can cause autosomal dominant hearing
loss.29,30 Furthermore, in the present study, USH patients from
different ethnolinguistic subgroups, namely Xhosa, Zulu, and
Sotho, were identified with this homozygous mutation,
negating genetic drift as a cause of the mutation.
The majority of sub-Saharan Africans speak ‘‘Bantu’’ languag-
es, which are believed to originate from a core region in the
north west of the African continent, specifically Nigeria and
western Cameroon.31 The ‘‘Bantu expansion’’ refers to the
movement of people approximately 5600 years ago, across and
down Africa. Bantu speakers arrived in South Africa approxi-
mately 1500 years ago, where they diverged further. Today, there
are two main Bantu-speaking groups in South Africa, the
Southeastern (subgroup S) and Southwestern (subgroups R
and K) groups. The S subgroup of languages comprises the
following ethnolinguistic groups: Sotho-Tswana, Venda and
Nguni (which includes Xhosa and Zulu).32 The different
ethnolinguistic groups described in this affected cohort,
therefore, represent a derivation of the original Bantu expan-
sion. All mutation-positive patients in the present study, whether
Xhosa, Zulu, or Sotho, shared a common haplotype spanning
>83kB of sequence which is 50 of the mutation. This denotes
that c.6377delC is a founder mutation that arose in speakers of
the S-subgroup of Bantu languages before their divergence.
The haplotype is imputed to be present in the 1000
Genomes data at a frequency of 10%, although the mutation is
not present on this haplotype in the African populations in east
Africa, that is, the Luhya of Kenya and in west Africa, that is,
the Yoruba of Nigeria. Furthermore, there is no linkage
disequilibrium of the three SNPs in these two populations,
implying that the c.6377delC mutation arose on the haplotype
after the Bantu speakers expanded southwards in Africa. A
limitation of this study is the sole use of the Yoruba and Luhya
data as proxy control populations, with which to investigate
the haplotype frequency. It has been shown that these
populations are genetically diverse from the Bantu-speaking
South Africans,32 and that proxy populations may not be
applicable due to the vast genetic diversity of African
populations.33 This study highlights the paucity of genetic
data from indigenous South Africans, as no local population
frequency data were available for the SNPs of interest in this
study in the SNP dataset recently made publically available by
Ramsay et al.32 This underscores the importance of the
Southern African Human Genome Programme (SAHGP)34 and
the Africa Genome Variation Project.27 Nevertheless, the use of
the Yoruba and Luyha datasets was valuable in showing that
this founder mutation arose as a more recent event: post-Bantu
expansion but predivergence into the different ethnolinguistic
groups of South Africa.
The 51 indigenous South African population controls used
in this study to establish the frequency of the mutation
comprises individuals speaking the S-group of Bantu languages
(including Xhosa, Zulu, and Sotho), although a complete and
defined ethnolinguistic breakdown of these samples is
unavailable. Nonetheless, a recent study on the genomic
structure of indigenous southern African populations shows
the relatively recent divergence of the Sotho-Tswana, Zulu, and
Xhosa populations, suggesting that these may serve as proxies
for one another, to a greater extent than the Luhya and/or
Yoruba.35 Thus, this cohort was appropriate to compare the
frequency of the mutation between cases and controls,
especially when supplemented by the 200 Zulu chromosomes
of the AGVP data.
Interestingly, 6 of the 10 homozygous mutation–positive
patients had been clinically diagnosed with type 2 USH, whereas
MYO7A mutations previously generally have been associated
with the more severe type 1 USH. This is not the first report of
MYO7A mutations causing type 2 USH,14 but the observation is
rare. The milder phenotype diagnosed could be due to the fact
that the mutation affects the C-terminal FERM domain, and less
than 4% of the protein is predicted to be truncated. A mouse
study of a different MYO7A mutation (albeit a splice variant),
affecting the same C-terminal FERM domain, showed tissue-
dependent mRNA instability36; truncated mRNA in the ear
appears to be degraded by nonsense-mediated decay, whereas
mRNA expressed in the retina is not. The majority of our




Frequency A/A (freq) A/G (freq) G/G (freq) C/C (freq) C/G (freq) G/G (freq) C/C (freq) C/T (freq) T/T (freq)
Case, n ¼ 6 6 (1.000) 0 (0.000) 0 (0.000) 6 (1.000) 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 6 (1.000)
Luyha control, n ¼ 97 14 (0.144) 45 (0.464) 38 (0.392) 46 (0.474) 44 (0.454) 7 (0.072) 28 (0.289) 49 (0.505) 20 (0.206)
Yoruba control, n ¼ 88 23 (0.261) 46 (0.523) 19 (0.216) 53 (0.602) 27 (0.307) 8 (0.091) 20 (0.227) 45 (0.511) 23 (0.261)
Total control, n ¼ 185 37 (0.200) 91 (0.492) 57 (0.308) 99 (0.535) 71 (0.384) 15 (0.081) 48 (0.259) 94 (0.508) 43 (0.232)
v2/df 21.320929/2 5.073668/2 17.951681/
df ¼ 2
Pearson’s P 2.35e-005* 0.079116 0.000126*
* P  0.001.
TABLE 5. Haplotype Reconstruction and Frequencies for rs6592706,
rs948972, rs11237122 in 6 USH Cases and 185 African Controls
Haplotype Case (freq) Control (freq) v2 Pearson’s P
A C C 0.00 (0.000) 70.59 (0.191) 2.947 0.086060
A C T 12.00 (1.000) 38.47 (0.104) 77.993 1.09e-018*†
A G C 0.00 (0.000) 35.20 (0.095) 1.313 0.251864
A G T 0.00 (0.000) 20.74 (0.056) 0.742 0.389170
G C C 0.00 (0.000) 53.38 (0.144) 2.106 0.146678
G C T 0.00 (0.000) 106.56 (0.288) 5.060 0.024500
G G C 0.00 (0.000) 30.83 (0.083) 1.135 0.286700
* The haplotype associated with c.6377delC.
† P  0.001.
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homozygous cohort reported congenital onset of USH, yet the
clinical diagnosis of USH type 2 indicated no vestibular
dysfunction is present and RP onset is later.
Mutations in MYO7A are associated with nonsyndromic
hearing loss20 and it would be interesting to evaluate whether
this particular founder mutation contributes to the burden of
hearing loss in indigenous South Africans and other African
populations. Our screening indicates that this mutation is not
associated with nonsyndromic RP, which is not surprising
given the lack of prior reports correlating MYO7A mutations
with RP, and the tissue-specific protein effects reported.36
Providing a genetic diagnosis to a family means that
individuals within that family can elect to have diagnostic,
carrier, or predictive testing. Genetic testing, therefore,
provides patients and their relatives with more accurate risks
of developing disease, upon which they can base their
informed life decisions and reproductive choices. The
identification of this founder mutation will allow targeted
genetic testing, based on clinical diagnosis and patient
ethnicity, which will reduce the costs of genetic testing and
facilitate a rapid test turnaround time. Although the
c.6377delC mutation was not present in 51 indigenous South
African controls, screening larger numbers of unaffected
controls from Xhosa, Zulu, and Sotho populations, and
combining these results with data from the AGVP27 and
SAHGP,34 will provide mutation carrier frequency information
that could be useful for genetic counseling purposes and risk
calculations. Further screening in larger cohorts of Mixed
Ancestry USH patients and nonsyndromic deafness patients is
warranted as these patients likely share some ancestry with
indigenous South Africans. Furthermore, there is potential for
identifying a large number of individuals with the same
pathogenic mutation, which could facilitate detailed genotype-
phenotype investigations37 and studies of phenotypic modifi-
ers. Finally, identification of these indigenous South African
patients with a MYO7A mutation is important given the
development of UshStat, the MYO7A gene replacement
therapy38 currently in trials (https://clinicaltrials.gov/ identi-
fiers NCT01505062 and NCT02065011).
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